Lubrizol LifeSciences

Articles

Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate the risk of missed doses. Moreover, they minimize toxicity and side effects, offering a more comfortable patient experience.
This article delves into the numerous benefits of long-acting drug delivery systems, including their ability to harness highly potent APIs, streamline development and intellectual property protection, and provide consistent drug release over extended periods. You’ll explore their applications in various medical fields, such as CNS disorders, cancers, diabetes, substance abuse, eye diseases, HIV treatment and prevention, and contraception.
Discover how Lubrizol Life Science – Health overcomes challenges in developing these innovative drug delivery systems and gain insights into successful long-acting drug development. Whether you’re a healthcare professional, researcher, or simply curious about the future of medicine, this article offers valuable knowledge and opens up new possibilities in patient care.


A Guide to Long-Acting Injectables and Implantables

 Iterion Therapeutics, a clinical stage biotechnology company, is dedicated to developing novel cancer therapeutics for a broad range of cancers. When Iterion’s lead product, Tegavivint, demonstrated low solubility in water, they needed a partner who could not only solve their bioavailability challenges, but also develop a scalable formulation with a viable manufacturing strategy. They turned to the experts at Lubrizol Life Science Health (LLS Health).
In this case study, you’ll learn how LLS Health combined its nanomilling expertise and GMP manufacturing capabilities to maximize bioavailability, improve patient experience, and take Iterion’s poorly soluble compound into clinical studies


Solving Solubility Challenges for a Novel Oncology Drug

CONRAD is a biomedical research and development organization dedicated to improving the reproductive health of women, especially in developing countries. They have developed a first-in-class, multipurpose intravaginal ring (IVR) that combines levonorgestrel with tenofovir to provide contraception while preventing against acquisition of Human Immunodeficiency Virus (HIV) and Herpes Simplex Virus (HSV).
To bring this novel concept into the clinic, CONRAD needed the support of a contract development and manufacturing organization (CDMO) with specialized expertise in long-acting implant and IVR development.
Lubrizol Life Science – Health was able to provide CONRAD with comprehensive support throughout the project from technology transfer to manufacturing. Their experts were proactive and creative in streamlining manufacturing of the product, and they integrated quality control and assurance from the very beginning of the project. As a result, we helped CONRAD to bring a novel, life-changing product to the clinic, and they are committed to helping other organizations develop and commercialize innovative drug eluting devices (DED).


Lubrizol Life Science Health partners with CONRAD to bring multipurpose IVR to the clinic

The eye’s anatomy is highly resistant to penetration of therapeutic agents, and successfully bypassing its protective barriers requires in-depth knowledge of ocular delivery, as well as specialized formulation and development expertise. In this guide, we will discuss how new and existing technologies can be employed to optimize ophthalmic formulations. We will then review the top considerations for an ocular drug delivery project to maximize the probability of success.
